CN109925333A - Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders - Google Patents
Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders Download PDFInfo
- Publication number
- CN109925333A CN109925333A CN201910367784.4A CN201910367784A CN109925333A CN 109925333 A CN109925333 A CN 109925333A CN 201910367784 A CN201910367784 A CN 201910367784A CN 109925333 A CN109925333 A CN 109925333A
- Authority
- CN
- China
- Prior art keywords
- parts
- capsule
- powder
- pharmaceutical composition
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a kind of pharmaceutical composition for treating prostatic disorders and capsule preparations and preparation method thereof.Pharmaceutical composition of the invention is made of the raw material of the component including following parts by weight: 10~30 parts of rape pollen, 45~80 parts of pumpkin seed oil, 0.01~0.10 part of lycopene, 3~10 parts of sophora bud powder, 2~9 parts of yeast powder and 2~10 parts of dandelion extract.Pharmaceutical composition of the invention can treat disease in the urological system caused by prostatic disorders and function and effect are significant.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions with treatment prostatic disorders, further relate to a kind of with treatment prostate
Capsule preparations of disease and preparation method thereof.
Background technique
Since rhythm of life is gradually accelerated, lead to the metabolic disturbance of male, kidney burden, so that before in recent years
The incidence of column gland disease is in rising trend, and has become the most common chronic disease of elderly men, severely compromises old
The health of year male.Prostatic disorders early stage, as lower urinary tract obstruction aggravates, symptom was gradually bright due to compensatory, atypical symptom
It is aobvious.Clinical symptoms include urine storage phase symptom, urinate phase symptom and post micturition symptoms, mainly include frequent micturition, urgent urination, the urinary incontinence,
Enuresis nocturna increases, dysuria, the symptoms such as urine retention, while with soreness of waist pain in the loins, weakness of limbs, spermatorrhea etc..
The drug and health food of the prevention and treatment prostatic disorders occurred currently on the market, mostly containing hormone and chemistry at
Point, it takes for a long time, serious side effect can be brought to human body, increases the burden of kidney.Therefore, people focus more on from traditional
It is found in integration of drinking and medicinal herbs, the health food of research and prevention and treatment prostatic disorders.CN103859412A discloses a kind of male health-care
Male health-care bioactive molecule in maca, Herba Cistanches and Radix Glycyrrhizae is developed into male health-care by food and preparation method thereof, the invention
Food, and maca, Herba Cistanches and Radix Glycyrrhizae are passed through into the bioavilability of nanotechnology raising bioactive molecule.Invention poison is secondary
Effect is smaller, has the function of adjusting endocrine, reduces prostatic disorders.CN109287828A discloses a kind of tomato yeast pressure
The pressed candy of piece candy and its preparation process, the invention are prepared by the raw material of following weight percent: rape pollen 17
~25%, pumpkin seed powder 16%~24%, yeast powder 3~9%, curcuma powder 4~10%, tomato meal 8~16%, isomaltose ketone
Sugar alcohol 18~26%, microcrystalline cellulose 6~14%, magnesium stearate 0.5~2% and hydroxymethyl, methyl cellulose 0.5~2%.It should
The formula of the pressed candy of invention is that pure plant is extracted, and toxic side effect is small, with tonifying kidney and strengthening yang, improves male reproductive function
Effect.Above-mentioned patent does not clearly state the therapeutic effect of urinary system problem caused by prostatic disorders.
Summary of the invention
The purpose of the present invention is to provide a kind of for treating the pharmaceutical composition of prostatic disorders, and flavour of a drug are less and treat
Effect is definite.
Another object of the present invention is to provide a kind of for treating the capsule preparations of prostatic disorders, the capsule preparations
Encapsulating performance, be protected from light function admirable.
A further object of the present invention is to provide a kind of method for preparing the capsule preparations, available encapsulating performance and
It is protected from light capsule preparations that newly can be excellent.
The purpose of the present invention is what is be achieved through the following technical solutions.
It is a kind of for treating the pharmaceutical composition of prostatic disorders, be made of the raw material of component for including following parts by weight:
10~30 parts of rape pollen, 45~80 parts of pumpkin seed oil, 0.01~0.10 part of lycopene, 3~10 parts of sophora bud powder, yeast powder 2
~9 parts and 2~10 parts of dandelion extract.
Pharmaceutical composition according to the present invention, it is preferable that described pharmaceutical composition is by the component including following parts by weight
Raw material is made: 13~22 parts of rape pollen, 60~80 parts of pumpkin seed oil, 0.03~0.08 part of lycopene, sophora bud powder 4~8
Part, 3~7 parts of yeast powder and 3~8 parts of dandelion extract.
Pharmaceutical composition according to the present invention, it is preferable that described pharmaceutical composition is made of the raw material of following parts by weight:
16 parts of rape pollen, 68.13 parts of pumpkin seed oil, 0.07 part of lycopene, 7 parts of sophora bud powder, 4.7 parts of yeast powder and
4.1 parts of dandelion extract；Or
14 parts of rape pollen, 64.87 parts of pumpkin seed oil, 0.04 part of lycopene, 7.5 parts of sophora bud powder, 6.5 parts of yeast powder
With 7.09 parts of dandelion extract；Or
20 parts of rape pollen, 66.63 parts of pumpkin seed oil, 0.07 part of lycopene, 5.3 parts of sophora bud powder, 4 parts of yeast powder and
4 parts of dandelion extract.
Pharmaceutical composition according to the present invention, it is preferable that the rape pollen pass through broken wall treatment, sporoderm-broken rate be 95% with
On.
Pharmaceutical composition according to the present invention, it is preferable that the yeast powder is Zinc-rich saccharomyces cerevisiae powder, and the content of Zn-ef ficiency is
2~8g/kg.
Pharmaceutical composition according to the present invention, it is preferable that the dandelion extract is the water extract of dandelion.
The present invention also provides a kind of capsule preparations, by the content and the receiving content that include aforementioned pharmaceutical compositions
Capsule crust constitute, the capsule crust is by including that the raw material of component of following parts by weight is made: 30~50 parts of water, glycerol 10
~25 parts, 30~50 parts of gelatin and 0.005~0.7 part of plant carbon black.
Capsule preparations according to the present invention, it is preferable that the weight ratio of water, glycerol and gelatin is 0.3~2:0.1~0.7:
0.3~2；The capsule crust with a thickness of 0.5~0.9mm.
The present invention also provides the preparation methods of above-mentioned capsule preparations, include the following steps:
(1) raw material needed for preparing content is uniformly mixed, and obtains content, and the raw material includes rape pollen, south
Melon seeds oil, lycopene, sophora bud powder, yeast powder and dandelion extract；
(2) water, glycerol, plant carbon black and gelatin are uniformly mixed, obtain glue, eliminate the bubble in the glue, and
Maintaining the glue temperature is 50~65 DEG C；
(3) after the glue being cooled to 30~40 DEG C, machine-shaping is obtained outside multiple capsules for sealing content
Skin；
(4) content described in the outer intracutaneous injection of Xiang Suoshu capsule, then cools down, obtains the capsule preparations.
Preparation method according to the present invention, it is preferable that in step (2), removed and removed photoresist using continuous heating method or vacuum method
Bubble in liquid；The temperature of the continuous heating method be 50~70 DEG C, heating time be 10~for 24 hours；The vacuum of the vacuum method
Degree is 0.03~0.095MPa, and the pumpdown time is 20~60min.
The thinking of pharmaceutical composition of the present invention is novel, and medication is accurate, by sophora bud powder with anti-oxidation function and kind
Lycopene, has effects that treat the rape pollen of hypertrophy of the prostate, dandelion and Zinc-rich saccharomyces cerevisiae powder with anti-inflammatory diuresis effect
Coordinated there is pharmaceutical composition of the invention to the urinary system problem that treatment prostatic disorders cause exact control
Therapeutic effect.Contain plant carbon black in the capsule crust of capsule preparations containing aforementioned pharmaceutical compositions of the invention, and controls
The ratio of water, glycerol and gelatin increases in capsule so that capsule preparations have preferable encapsulating performance and are protected from light performance
Tolerant stability.
Specific embodiment
The present invention is further illustrated combined with specific embodiments below, but protection scope of the present invention is not limited to
This.
< pharmaceutical composition >
The pharmaceutical composition with treatment prostatic disorders of the invention, by the raw material system of the component including following parts by weight
At: 10~30 parts of rape pollen, 45~80 parts of pumpkin seed oil, 0.01~0.10 part of lycopene, 3~10 parts of sophora bud powder, yeast
2~9 parts and 2~10 parts of dandelion extract of powder.In certain embodiments, described pharmaceutical composition by following parts by weight original
Material is made: 10~30 parts of rape pollen, 45~80 parts of pumpkin seed oil, 0.01~0.10 part of lycopene, 3~10 parts of sophora bud powder,
2~9 parts and 2~10 parts of dandelion extract of yeast powder.
Rape pollen in the present invention passes through broken wall treatment, and sporoderm-broken rate is 95% or more, preferably 98% or more.Broken wall
The percentage of rate can be percent by volume.Wall breaking technology refers to utilizing ultra micro breaking techniques by rape pollen blastema wall
It decomposes, cytoplasm is exposed sufficiently, guarantee that the flavonoid glycoside compound in rape pollen can be by suction quickly and efficiently
It receives.The content of the rape pollen is 10~30 parts by weight, preferably 13~22 parts by weight, more preferably 14~20 parts by weight.
The content of rape pollen is moderate, can cause resulting pharmaceutical composition viscosity big to avoid too high levels, so that be prepared
Capsule preparations are easy to appear the phenomenon that leakage.
Lycopene in the present invention can be the lycopene handled by physics micro-capsule embedding techniques or common
Lycopene；Preferably the former.The physics micro-capsule embedding techniques refer to using suitable coated fertilizer, as natural plant gum, polysaccharide,
The macromolecular compounds such as starch, cellulose or protein, lycopene is sealed up for safekeeping becomes one kind in a kind of microencapsulation
The technology of solia particle product can substantially reduce the rate of decay during lycopene storage, make to play in lycopene
The active factors of oxidation resistance are in enclosure space, hence it is evident that the degradation speed of active factors are reduced, so that active factors be made to obtain
To being effectively protected.The content of lycopene be 0.01~0.10 parts by weight, preferably 0.03~0.08 parts by weight, more preferably
For 0.04~0.07 parts by weight.
Yeast powder in the present invention can be Zinc-rich saccharomyces cerevisiae powder.In terms of yeast powder total amount, the content of Zn-ef ficiency is 2~8g/
Kg, preferably 3~6g/kg.Zinc-rich saccharomyces cerevisiae powder refers to is added Zn-ef ficiency during Yeast Cultivation, meeting during yeast growth
Absorbed and made Zn-ef ficiency and the intracorporal protein of yeast and polysaccharide organically combine and form organic zinc to Zn-ef ficiency, it can be with
Eliminating inorganic zinc stimulates the toxic side effect and stomach of human body, enables the utilization that is absorbed by the body that Zn-ef ficiency is more efficient, safe.
The content of yeast powder in the present invention is 2~9 parts by weight, preferably 3~7 parts by weight, more preferably 4~6.5 parts by weight.
Dandelion extract in the present invention is dandelion water extract or taraxol extract, and preferably dandelion water mentions
Object.According to embodiment of the present invention, the method that dandelion water extract is made is self-heating reflux extraction, ultrasonic extraction
Method or decocting method, preferably heating and refluxing extraction method or decocting method, more preferably decocting method.Extraction time is 1~3 time, preferably
It is 1~2 time, more preferably 1 time.Each extraction time is 0.5~2.5 hour, preferably 1~2 hour, more preferably 1.5
~2 hours.Each amount of water is 6~15 times of dandelion weight, preferably 8~13 times, more preferably 9~11 times.According to this
One embodiment of invention extracts dandelion 1 time using decocting method, and extraction time is 2 hours, and amount of water is dandelion weight
10 times of amount, filtering, resulting filtrate is dandelion water extract.The content of the dandelion extract is 2~10 parts by weight,
Preferably 3~8 parts by weight, more preferably 4~7.5 parts by weight.
The content of pumpkin seed oil in the present invention is 45~80 parts by weight, preferably 60~80 parts by weight, more preferably 64
~70 parts by weight.The content of sophora bud powder is 3~10 parts in the present invention, preferably 4~8 parts by weight, more preferably 5~7.5 weight
Part.
According to embodiment of the present invention, described pharmaceutical composition by include following parts by weight component raw material system
At: 13~22 parts of rape pollen, 60~80 parts of pumpkin seed oil, 0.03~0.08 part of lycopene, 4~8 parts of sophora bud powder, yeast powder
3~7 parts and 3~8 parts of dandelion extract.A preferred embodiment according to the present invention, described pharmaceutical composition is by as follows
The raw material of the component of parts by weight is made: 13~22 parts of rape pollen, 60~80 parts of pumpkin seed oil, lycopene 0.03~0.08
Part, 4~8 parts of sophora bud powder, 3~7 parts of yeast powder and 3~8 parts of dandelion extract.
A specific embodiment according to the present invention, described pharmaceutical composition is by the raw material system including following parts by weight
At: 16 parts of rape pollen, 68.13 parts of pumpkin seed oil, 0.07 part of lycopene, 7 parts of sophora bud powder, 4.7 parts of yeast powder and dandelion
4.1 parts of extract.Another embodiment according to the present invention, described pharmaceutical composition is by the original including following parts by weight
Material is made: 14 parts of rape pollen, 64.87 parts of pumpkin seed oil, 0.04 part of lycopene, 7.5 parts of sophora bud powder, 6.5 parts of yeast powder and
7.09 parts of dandelion extract.Another specific embodiment according to the present invention, described pharmaceutical composition is by including following weight
The raw material of amount part is made: 20 parts of rape pollen, 66.63 parts of pumpkin seed oil, 0.07 part of lycopene, 5.3 parts of sophora bud powder, yeast
4 parts and 4 parts of dandelion extract of powder.
A specific embodiment according to the present invention, described pharmaceutical composition are made of the raw material of following parts by weight: oil
16 parts of cauliflower powder, 68.13 parts of pumpkin seed oil, 0.07 part of lycopene, 7 parts of sophora bud powder, 4.7 parts of yeast powder and dandelion are extracted
4.1 parts of object.Another embodiment according to the present invention, described pharmaceutical composition are made of the raw material of following parts by weight:
14 parts of rape pollen, 64.87 parts of pumpkin seed oil, 0.04 part of lycopene, 7.5 parts of sophora bud powder, 6.5 parts of yeast powder and dandelion
7.09 parts of extract.Another specific embodiment according to the present invention, described pharmaceutical composition by following parts by weight raw material
It is made: 20 parts of rape pollen, 66.63 parts of pumpkin seed oil, 0.07 part of lycopene, 5.3 parts of sophora bud powder, 4 parts of yeast powder and Pu
4 parts of public English extract.
Described pharmaceutical composition may include pharmaceutically acceptable auxiliary material, the type of the pharmaceutically acceptable auxiliary material
With no restrictions.Described pharmaceutical composition can be preparation, and the preparation is preferably oral preparation, and the dosage form of the oral preparation is not
It is limited, preferably tablet, pill, capsule, granule, suspension or oral agents, more preferably capsule.In capsule
Content is preferably liquid, is easier to be absorbed by the body.
The Quercetin of the sophora bud powder containing anti-oxidation function in pharmaceutical composition of the present invention, cooperation have anti-oxidation function
And the lycopene of prevention and treatment prostate cancer, in conjunction with the dandelion with anti-inflammatory diuresis effect, and Zinc-rich saccharomyces cerevisiae powder is combined, supplement
Organic zinc is able to maintain that the normal physiological function of prostate, has preferable treatment to prostatic disorders.Simultaneously on the south the present invention
As base-material, pumpkin seed oil inside is contained can eliminate prostate initial stage swelling and prevention and prevent and treat urinary system disease melon seeds oil
The pumpkin element of disease.Collocation can inhibit the biological effect of dihydrotestosterone, and be adjustable the function of vesicourethral smooth muscle, make hyperplasia
Body of prostate reverse approximate normal rape pollen.The coordinated of mentioned component can be such that pharmaceutical composition of the invention has
Good prevention and the effect of alleviation prostatic disorders.
< capsule preparations >
Capsule preparations of the invention are by including outside the content of aforementioned pharmaceutical compositions and the capsule of the receiving content
Skin is constituted.Capsule crust is made of the raw material of the component including following parts by weight: 30~50 parts of water, 10~25 parts of glycerol, gelatin
30~50 parts and 0.005~0.7 part of plant carbon black.In certain embodiments, capsule crust by following parts by weight component
Raw material is made: 30~50 parts of water, 10~25 parts of glycerol, 30~50 parts of gelatin and 0.005~0.7 part of plant carbon black.Of the invention
Capsule crust, so that capsule preparations are protected from light performance with good, avoids interior inside capsule preparations due to containing plant carbon black
It is tolerant to be decomposed due to the irradiation by light, lead to active reduction.
The parts by weight of water are 30~50 parts, preferably 35~48 parts, more preferably 38~43 parts in the present invention.Water can be with
For distilled water, deionized water, pure water or ultrapure water, preferably distilled water or deionized water, more preferably distilled water.The present invention
In glycerol parts by weight be 10~25 parts, preferably 13~22 parts, more preferably 15~19 parts.Setting can be to avoid in this way
Glycerol excessively will lead to capsule and be adhered, and capsule is easily deformed.Gelatin parts by weight in the present invention are 30~50 parts, preferably 35~
45 parts, more preferably 38~43 parts.A preferred embodiment according to the present invention, water, glycerol and gelatin in capsule crust
Weight ratio be 2~10:1~7:2~10, preferably 2~7:1~2.5:2~7, more preferably 2~4:1~2.5:2~4.
Setting can guarantee that the soft or hard degree of capsule crust is moderate in this way, increase the encapsulating performance of capsule crust.Plant charcoal in the present invention
Black parts by weight are 0.05~0.7 part, preferably 0.1~0.6 part, more preferably 0.2~0.5 part.One according to the present invention
Preferred embodiment, the amount of plant carbon black be water, glycerol, gelatin and plant carbon black gross mass 2~7 ‰, preferably 2~
5 ‰, more preferably 2~4 ‰.
According to embodiment of the present invention, the capsule crust by include following parts by weight component raw material system
At: 35~48 parts of water, 13~22 parts of glycerol, 35~45 parts of gelatin and 0.1~0.6 part of plant carbon black.
A specific embodiment according to the present invention, the capsule crust are made of the raw material of following parts by weight: water
41.54 parts, 16.62 parts of glycerol, 41.54 parts of gelatin and 0.3 part of plant carbon black.Another specific embodiment party according to the present invention
Formula, the capsule crust are made of the raw material of following parts by weight: 42.21 parts of water, 18.34 parts of glycerol, 39.03 parts of gelatin and plant
0.42 part of carbon black.Another specific embodiment according to the present invention, the capsule crust are made of the raw material of following parts by weight:
39.72 parts of water, 18.31 parts of glycerol, 41.67 parts of gelatin and 0.30 part of plant carbon black.
In the present invention capsule crust with a thickness of 0.5~0.9mm, preferably 0.55~0.8mm, more preferably 0.6~
0.7mm.The encapsulating performance that can be further improved capsule is set in this way.
The preparation method > of < capsule preparations
The preparation method of capsule preparations of the invention, includes the following steps:
(1) raw material needed for preparing content is uniformly mixed, and obtains content, and the raw material includes rape pollen, south
Melon seeds oil, lycopene, sophora bud powder, yeast powder and dandelion extract；Specific proportion is as previously described.
(2) water, glycerol, plant carbon black and gelatin are uniformly mixed, obtain glue, eliminate the bubble in the glue, and
Maintaining the glue temperature is 50~65 DEG C；Specific proportion is as previously described.
(3) after the glue being cooled to 30~40 DEG C, machine-shaping is obtained outside multiple capsules for sealing content
Skin, the capsule crust with a thickness of 0.5~0.9mm.
(4) content described in intracutaneous injection to outside each capsule, it is cooling, obtain the capsule preparations.
In step (1), the acquisition methods of dandelion extract are as previously mentioned, details are not described herein again.It prepares needed for content
The hybrid mode of raw material can be by the solid component in raw material such as rape pollen, lycopene, sophora bud powder, dandelion extract
It crushes and is uniformly mixed with yeast powder, obtain the first mixture；It disperses the first mixture in pumpkin seed oil and obtains content.
In step (2), under the conditions of 80~85 DEG C, water, glycerol and gelatin is uniformly mixed to get the second mixture, will be planted
Object carbon black is dispersed in second mixture, stirring 1h or so, until invisible particulate matter, obtains glue.It removes
Bubble in glue uses continuous heating method or vacuum method.The continuous heating method, which refers to, holds gained glue with heat source
Continuous heating, the bubble in glue is driven out of.The temperature of continuous heating method is 50~70 DEG C, preferably 55~65 DEG C.Heating time
For 10~for 24 hours, preferably 12~20h, more preferably 14~16h.Guarantee that the bubble in glue is sufficiently driven out of.The vacuum
Method is will to accommodate the container progress vacuumize process of glue, reduces the pressure in container, the bubble in glue is discharged.It is described
The vacuum degree of vacuum method is 0.03~0.095MPa, preferably 0.05~0.085Mpa.Pumpdown time is 20~60min, excellent
It is selected as 30~40min.The bubble in glue can be effectively removed in this way, avoid influencing outside capsule in capsule crust containing bubble
The quality of skin.Maintaining glue temperature is 50~65 DEG C, preferably 60~65 DEG C, prevents from that new bubble can be mixed into when glue is cooling.
In step (3), the glue is cooled to 30~40 DEG C, preferably 35~40 DEG C, cooling solidifies glue slightly,
Guarantee can be with machine-shaping.The capsule crust is bonded by two capsule shell fissions.Each capsule shell is seperated
It is open at one end, and shape is class hemispherical, can be used to accommodate content, the opening of two capsule shell fissions is bonded in one
Play the capsule crust formed for sealing the content contained in two capsule shell fissions.Capsule shell fission with
And capsule crust with a thickness of 0.5~0.9mm, preferably 0.55~0.8mm, more preferably 0.6~0.7mm.Setting can in this way
To further increase the encapsulating performance of capsule.A preferred embodiment according to the present invention, is cooled to 35~40 for glue
DEG C, machine-shaping obtain it is multiple can accommodate content and capsule shell open at one end is seperated, capsule shell it is seperated with a thickness of
0.55~0.8mm.
In step (4) of the present invention, the method for intracutaneous injection content is to outside capsule, infuses into each capsule shell fission
Enter content, and the interface of two capsule shell fissions is bonded, to get capsule preparations after cooling.
A preferred embodiment according to the present invention, the preparation method of capsule preparations of the present invention include the following steps:
(1) rape pollen, lycopene, sophora bud powder and yeast powder are crushed and is uniformly mixed, obtain the first mixture；It will
First mixture is dissolved in pumpkin seed oil, obtains content；
Under the conditions of (2) 80~85 DEG C, water, glycerol and gelatin are uniformly mixed to get the second mixture, plant carbon black is equal
It is even to be scattered in second mixture and stir 1h or so, obtain glue；Using the bubble in continuous heating method discharge glue, add
Hot temperature is 55~65 DEG C, and heating time is 12~20h, then maintains glue temperature at 60~65 DEG C；
(3) glue is cooled to 35~40 DEG C, machine-shaping obtains multiple contents and open at one end of capable of accommodating
Capsule shell is seperated, capsule shell it is seperated with a thickness of 0.55~0.8mm；
(4) divide content described in internal injection to each capsule shell, two are accommodated the glue of content
The opening of capsule shell fission bonds, and after cooling, obtains capsule preparations.
Embodiment 1
(1) by according to the formula in table 1, rape pollen, sophora bud powder, yeast powder and lycopene that sporoderm-broken rate is 99% are crushed
And be uniformly mixed, obtain the first mixture；First mixture is dissolved in pumpkin seed oil, content is obtained.
(2) according to the formula of table 2, water, glycerol and gelatin are uniformly mixed to get the second mixture at 83 DEG C, by plant
Carbon black is dispersed in second mixture and stirs 1h or so, obtains glue；Using in continuous heating method discharge glue
Bubble, heating temperature are 60 DEG C, heating time 14h, then maintain glue temperature at 60 DEG C.
(3) glue is cooled to 40 DEG C, machine-shaping obtains multiple to accommodate content and capsule open at one end
Shell is seperated, capsule shell it is seperated with a thickness of 0.7mm；
(4) divide content described in internal injection to capsule shell, two are accommodated the capsule shell point of content
The opening of body bonds, and after cooling, obtains capsule preparations.
Table 1
| Title | Rape pollen | Lycopene | Sophora bud powder |
| Dosage (parts by weight) | 16 | 0.07 | 7 |
| Title | Zinc-rich saccharomyces cerevisiae powder | Pumpkin seed oil | Dandelion water extract |
| Dosage (parts by weight) | 4.7 | 68.13 | 4.1 |
Table 2
| Title | Water | Glycerol | Gelatin | Plant carbon black |
| Dosage (parts by weight) | 41.54 | 16.62 | 41.54 | 0.3 |
Embodiment 2
Content is replaced with into formula shown in table 3, glue is replaced with into formula shown in table 4, remaining and 1 phase of embodiment
Together.
Table 3
| Title | Rape pollen | Lycopene | Sophora bud powder |
| Dosage (parts by weight) | 14 | 0.04 | 7.5 |
| Title | Zinc-rich saccharomyces cerevisiae powder | Pumpkin seed oil | Dandelion water extract |
| Dosage (parts by weight) | 6.5 | 64.87 | 7.09 |
Table 4
| Title | Water | Glycerol | Gelatin | Plant carbon black |
| Dosage (parts by weight) | 42.21 | 18.34 | 39.03 | 0.42 |
Embodiment 3
Content is replaced with into formula shown in table 5, glue is replaced with into formula shown in table 6, remaining and 1 phase of embodiment
Together.
Table 5
| Title | Rape pollen | Lycopene | Sophora bud powder |
| Dosage (parts by weight) | 20 | 0.07 | 5.3 |
| Title | Zinc-rich saccharomyces cerevisiae powder | Pumpkin seed oil | Dandelion water extract |
| Dosage (parts by weight) | 4 | 66.63 | 4 |
Table 6
| Title | Water | Glycerol | Gelatin | Plant carbon black |
| Dosage (parts by weight) | 39.72 | 18.31 | 41.67 | 0.30 |
Embodiment 4
Will in step (2) using the bubble in continuous heating method discharge glue, heating temperature is 60 DEG C, and heating time is
14h is replaced with using the bubble in vacuum method discharge glue, vacuum degree 0.08Mpa, pumpdown time 30min, remaining step
It is rapid same as Example 1.
Comparative example 1
The Central-South melon seeds oil of content composition formula is replaced with into soybean oil, remaining is same as Example 1.
Comparative example 2
Rape pollen in content composition formula is replaced with into cordate houttuynia, remaining is same as Example 1.
Experimental example 1- sensory evaluation
Sensory testing carried out to the capsule preparations of embodiment 1, sensory evaluation criteria referring to table 7, sensory evaluation group by
30 volunteers composition, test result is referring to table 8.
7 sensory evaluation criteria of table
8 test result of table
| Project | Capsule appearance | Capsule coat color | Capsule crust mouthfeel | Whether content is visible |
| Score | 4.6 | 4.933 | 4.767 | 4.8 |
| Project | Content color | Content smell | Content mouthfeel | |
| Score | 4.87 | 4.67 | 4.47 |
Note: score is the average value of 30 parts of appraisal results.
Experimental example 2- efficacy assessments
Diagnostic criteria: urination situation includes urgent urination, frequent micturition, urodynia, urine waiting, urine retention, frequent urination at night；Physical attributes include
Soreness of waist pain in the loins, weakness of limbs, spermatorrhea.
Case selection: it makes a definite diagnosis with above-mentioned urination symptom and male's case of physical attributes 18, the age 45 years old or more.
3 groups are equally divided into, every group of 6 people.Instructions of taking: three groups respectively examination take embodiment 1, the capsule system that comparative example 1 to 2 is prepared
Agent.1 time a day, 4 tablets each time, it continuously takes 15 days, urination situation and somatic reaction during observation is taken.
Experimental result: the results are shown in Table 9 for the examination of embodiment 1 clothes, and the results are shown in Table 10 for the examination of comparative example 1 clothes, and comparative example 2 is tried
It is as shown in table 11 to take result.
Table 9
As known from Table 9, the capsule preparations of embodiment 1 all have in various degree the disease in the urological system that each patient occurs
Therapeutic effect, to treatment the disease in the urological system definite effect as caused by prostate.
Table 10
Table 11
By table 10 and table 11 it is found that comparative example 1, the urinary system that most of patient occur in the capsule preparations of comparative example 2
Disease has a different degrees of therapeutic effect, but every group to rule therapeutic effect by men unobvious, and onset time does not implement
Example 1 occurs fast.
Present invention is not limited to the embodiments described above, without departing from the essence of the present invention, this field skill
Any deformation, improvement, the replacement that art personnel are contemplated that each fall within the scope of the present invention.
Claims (10)
1. a kind of for treating the pharmaceutical composition of prostatic disorders, which is characterized in that described pharmaceutical composition is by including as follows
The raw material of the component of parts by weight is made:
10~30 parts of rape pollen, 45~80 parts of pumpkin seed oil, 0.01~0.10 part of lycopene, 3~10 parts of sophora bud powder, yeast
2~9 parts and 2~10 parts of dandelion extract of powder.
2. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition is by including following parts by weight
The raw material of component be made:
13~22 parts of rape pollen, 60~80 parts of pumpkin seed oil, 0.03~0.08 part of lycopene, 4~8 parts of sophora bud powder, yeast
3~7 parts and 3~8 parts of dandelion extract of powder.
3. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition by following parts by weight original
Material is made:
16 parts of rape pollen, 68.13 parts of pumpkin seed oil, 0.07 part of lycopene, 7 parts of sophora bud powder, 4.7 parts of yeast powder and dandelion
4.1 parts of extract；Or
14 parts of rape pollen, 64.87 parts of pumpkin seed oil, 0.04 part of lycopene, 7.5 parts of sophora bud powder, 6.5 parts of yeast powder and Pu are public
7.09 parts of English extract；Or
20 parts of rape pollen, 66.63 parts of pumpkin seed oil, 0.07 part of lycopene, 5.3 parts of sophora bud powder, 4 parts of yeast powder and dandelion
4 parts of extract.
4. described in any item pharmaceutical compositions according to claim 1~3, which is characterized in that the rape pollen passes through broken wall
Processing, sporoderm-broken rate are 95% or more.
5. described in any item pharmaceutical compositions according to claim 1~3, which is characterized in that the yeast powder is Zinc-rich saccharomyces cerevisiae
Powder, and the content of Zn-ef ficiency is 2~8g/kg.
6. described in any item pharmaceutical compositions according to claim 1~3, which is characterized in that the dandelion extract is Pu
The water extract of public English.
7. a kind of capsule preparations, which is characterized in that the capsule preparations are by including the described in any item drugs of claim 1~6
The content of composition and the capsule crust for accommodating the content are constituted, and the capsule crust is by the group including following parts by weight
The raw material divided is made: 30~50 parts of water, 10~25 parts of glycerol, 30~50 parts of gelatin and 0.005~0.7 part of plant carbon black.
8. capsule preparations according to claim 7, which is characterized in that the weight ratio of water, glycerol and gelatin be 2~10:1~
7:2~10；The capsule crust with a thickness of 0.5~0.9mm.
9. being included the following steps: according to the preparation method of the described in any item capsule preparations of claim 7~8
(1) raw material needed for preparing content is uniformly mixed, and obtains content, and the raw material includes rape pollen, pumpkin
Oil, lycopene, sophora bud powder, yeast powder and dandelion extract；
(2) water, glycerol, plant carbon black and gelatin are uniformly mixed, obtain glue, eliminate the bubble in the glue, and maintain
The glue temperature is 50~65 DEG C；
(3) after the glue being cooled to 30~40 DEG C, machine-shaping is obtained multiple for sealing the capsule crust of content；
(4) content described in the outer intracutaneous injection of Xiang Suoshu capsule, then cools down, obtains the capsule preparations.
10. according to the method described in claim 9, it is characterized in that, in step (2), using continuous heating method or vacuum method
Remove the bubble in glue；The temperature of the continuous heating method be 50~70 DEG C, heating time be 10~for 24 hours；The vacuum method
Vacuum degree be 0.03~0.095MPa, the pumpdown time be 20~60min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910367784.4A CN109925333A (en) | 2019-05-05 | 2019-05-05 | Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910367784.4A CN109925333A (en) | 2019-05-05 | 2019-05-05 | Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109925333A true CN109925333A (en) | 2019-06-25 |
Family
ID=66991332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910367784.4A Pending CN109925333A (en) | 2019-05-05 | 2019-05-05 | Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109925333A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736396A (en) * | 2004-08-16 | 2006-02-22 | 新疆特丰药业股份有限公司 | Compound lycopene formulation for men and preparation process thereof |
| US20070298097A1 (en) * | 2006-04-03 | 2007-12-27 | Dominic Natural Biotech Inc. | Multi-carotenoids compositions and uses therefor |
| CN106266076A (en) * | 2015-09-23 | 2017-01-04 | 洛阳华以生物工程有限公司 | A kind of health caring product prescription improving prostatic function |
| CN109287828A (en) * | 2018-10-23 | 2019-02-01 | 上海屹泽生物科技有限公司 | A kind of tomato yeast tablet candy fruit and its preparation process |
-
2019
- 2019-05-05 CN CN201910367784.4A patent/CN109925333A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736396A (en) * | 2004-08-16 | 2006-02-22 | 新疆特丰药业股份有限公司 | Compound lycopene formulation for men and preparation process thereof |
| US20070298097A1 (en) * | 2006-04-03 | 2007-12-27 | Dominic Natural Biotech Inc. | Multi-carotenoids compositions and uses therefor |
| CN106266076A (en) * | 2015-09-23 | 2017-01-04 | 洛阳华以生物工程有限公司 | A kind of health caring product prescription improving prostatic function |
| CN109287828A (en) * | 2018-10-23 | 2019-02-01 | 上海屹泽生物科技有限公司 | A kind of tomato yeast tablet candy fruit and its preparation process |
Non-Patent Citations (3)
| Title |
|---|
| 姚秋萍: "《油菜花粉超微有效成分溶出、代谢特征及指纹图谱研究》", 31 October 2014, 西南交通大学出版社 * |
| 李坤: "油菜花粉抗前列腺增生与炎症的活性部位研究", 《中草药》 * |
| 李超: "《前列腺病防治指南》", 30 November 2006, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN103251873A (en) | Traditional Chinese veterinary medicine capable of helping to digest and remove retention | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN100443074C (en) | Heat-clearing and stranguria-relieving Chinese medicine preparation and production thereof | |
| CN101933963B (en) | Nasal in-situ gel for treating headache | |
| CN101926896B (en) | Traditional Chinese medicinal preparation for treating gout and preparation method thereof | |
| CN102895620A (en) | Preparation technology and production method for integrated new formulation of licorice heart-draining decoction | |
| CN101040891B (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN109925333A (en) | Pharmaceutical composition and the capsule preparations and preparation method thereof for treating prostatic disorders | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN102258557B (en) | Medicament for treating prostatic hyperplasia | |
| KR100522176B1 (en) | Composition for improving male sexual function | |
| CN114712446A (en) | Traditional Chinese medicine composition and preparation for treating stomach diseases and preparation method thereof | |
| CN110917249A (en) | Traditional Chinese medicine composition for prostate and preparation method and application thereof | |
| Bhardwaj et al. | Development of cucurbocitrin based nutraceutical formulation: A potential adjuvant herbal therapy in the management of hypertension | |
| CN100531765C (en) | Pinellia tuber extract and its preparation process, medicine composition and use | |
| JPH0733676A (en) | Composition for lowering blood suger value | |
| CN102579601A (en) | Medicinal composition for treating rheumatoid arthritis, and preparation method and application thereof | |
| CN114931600B (en) | Traditional Chinese medicine composition for preventing and treating altitude stress and preparation method thereof | |
| CN106668329A (en) | Botanical formula for treatment of benign prostatic hyperplasia and preparation method thereof | |
| CN1985900B (en) | Colon-targeting oral compound rubarb preparation | |
| CN102218106B (en) | Traditional Chinese medicine composition for treating deficiency of liver and kidney and preparation method thereof | |
| CN101239167B (en) | Medicaments for treating hysteromyoma | |
| CN105535429A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190625 |